Clinical Trials Browser

Phase 2 × INDUSTRY × ropidoxuridine × Clear all

NCT06359379 2025-12-18

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Phase 2 Terminated

Glioblastoma